TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07826455: Diagnostic Value of Early Response to Tegoprazan in Symptomatic GERD Patients: An Exploratory Clinical Study

Sponsor: HK inno.N Corporation · Phase: PHASE4 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 100 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,499,200

Rescue Site Savings

+$5,604,160

Unlock Full NCT07826455 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07826455 Rescue Dossier →